荟萃分析:合并原发性硬化性胆管炎的炎症性肠病患者中高级疗法的安全性与有效性
该系统评价与荟萃分析评估了成人PSC-IBD患者使用高级IBD疗法的安全性和有效性,纳入5项回顾性病例系列共394例,使用英夫利西单抗、阿达木单抗、维得利珠单抗和托法替布。汇总3个月临床缓解率为24.7%,6-12个月为28.6%,无激素缓解率45.4%,黏膜愈合率25.6%,因不良事件停药率9.1%。结论认为疗效中等但令人鼓舞,安全性可接受,但证据受回顾性设计和小样本限制。
要点
- PSC-IBD患者使用高级疗法3个月临床缓解率24.7%,6-12个月28.6%。
- 无激素缓解率45.4%,黏膜愈合率25.6%,因不良事件停药率9.1%。
- 结直肠肿瘤汇总比例10.5%,结直肠癌4.3%,胆管癌0.8%。
核心结论
- 高级IBD疗法在PSC-IBD中显示中等但令人鼓舞的有效性和可接受的安全性。
- 现有证据受回顾性设计、小样本和显著临床与方法学异质性限制。
- 需要采用标准化IBD结局的前瞻性对照研究来指导该高危人群的最佳治疗策略。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE、Embase、Cochrane和Web of Science至2026年7月。
- 纳入5项回顾性病例系列,共394例成人PSC-IBD患者,评估英夫利西单抗、阿达木单抗、维得利珠单抗和托法替布。
- 中位随访18.4个月,采用随机效应模型进行汇总估计。
- 主要结局为IBD临床缓解,次要结局包括临床应答、无激素缓解、黏膜愈合、不良事件相关停药和结直肠肿瘤。
主要发现
- 汇总临床缓解率3个月为24.7%(95%CI:17.2%-33.0%),6-12个月为28.6%(95%CI:16.3%-42.6%)。
- 无激素缓解率45.4%(95%CI:33.1%-57.9%),黏膜愈合率25.6%(95%CI:13.6%-39.5%)。
- 托法替布在单一研究中临床应答率59.3%(95%CI:40.0%-77.2%),不良事件率低。
- 不良事件相关停药率9.1%(95%CI:4.4%-15.1%),原发无应答或继发失应答率31.8%(95%CI:25.5%-38.5%)。
- 结直肠肿瘤汇总比例10.5%(12/112;95%CI:5.3%-17.1%),结直肠癌4.3%(5/112),胆管癌0.8%(2/177)。
临床怎么用
- 在PSC-IBD患者中使用高级疗法时,应预期中等疗效并监测原发无应答或继发失应答。
- 治疗期间需关注不良事件相关停药风险,并鉴于结直肠肿瘤比例较高,应重视结直肠肿瘤监测。
- 托法替布可能具有较高临床应答率和较低不良事件率,但证据仅来自单一研究。
局限性
- 纳入研究均为回顾性病例系列,存在选择偏倚和回忆偏倚。
- 样本量小(共394例),部分结局数据不完整。
- 临床和方法学异质性显著,影响汇总估计的可靠性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC) is a distinct phenotype (PSC-IBD). Data on the safety and effectiveness of advanced IBD therapies on IBD outcomes in PSC-IBD remain limited. METHODS: A systematic review and meta-analysis assessed the safety and effectiveness of advanced therapies in adults with PSC-IBD. MEDLINE, Embase, Cochrane databases and Web of Science were searched to July 2026. The primary outcome was IBD clinical remission. Secondary outcomes included clinical response, corticosteroid-free remission, mucosal healing, adverse event-related treatment discontinuation and colorectal neoplasia. A random-effects model was used for pooled estimates. RESULTS: Five retrospective case-series (n = 394) evaluating infliximab, adalimumab, vedolizumab and tofacitinib were included (median follow-up of 18.4 months). Pooled clinical remission rates were 24.7% (95% CI: 17.2%-33.0%) at 3 months and 28.6% (95% CI: 16.3%-42.6%) at 6-12 months. Corticosteroid-free remission was achieved in 45.4% (95% CI: 33.1%-57.9%) and mucosal healing in 25.6% (95% CI: 13.6%-39.5%). Tofacitinib was associated with a clinical response rate of 59.3% (95% CI: 40.0%-77.2%) and low adverse event rate, in a single available study. Adverse event-related discontinuation occurred in 9.1% (95% CI: 4.4%-15.1%), while 31.8% (95% CI: 25.5%-38.5%) experienced primary non-response or secondary loss of response. The pooled proportion of colorectal neoplasia was 10.5% (12/112; 95% CI: 5.3%-17.1%). Five patients developed colorectal cancer (5/112; 4.3%) and two (2/177; 0.8%) cholangiocarcinoma. CONCLUSION: Advanced IBD therapies demonstrate modest but encouraging effectiveness and an acceptable safety profile in PSC-IBD; however, the available evidence is limited by retrospective study designs, small sample sizes and substantial clinical and methodological heterogeneity. Prospective controlled studies using standardised IBD outcomes are needed to inform optimal therapeutic strategies in this high-risk population. TRIAL REGISTRATION: PROSPERO: CRD42024580296.
引用
- Elzubeir A, Kumar A, McArdle A, et al. Meta-Analysis: Safety and Effectiveness of Advanced Therapies in Inflammatory Bowel Disease Patients With Concomitant Primary Sclerosing Cholangitis. Aliment Pharmacol Ther. 2026. PMID: 42904527. doi:10.1111/apt.71045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。